| 1.05 -0.05 (-4.55%) | 02-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.44 |
1-year : | 1.57 |
| Resists | First : | 1.23 |
Second : | 1.35 |
| Pivot price | 1.11 |
|||
| Supports | First : | 1.04 |
Second : | 0.86 |
| MAs | MA(5) : | 1.08 |
MA(20) : | 1.13 |
| MA(100) : | 1.17 |
MA(250) : | 1.18 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 15.4 |
D(3) : | 17.2  |
| RSI | RSI(14): 39.6 |
|||
| 52-week | High : | 1.54 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ANTX ] has closed above bottom band by 16.1%. Bollinger Bands are 3.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.1 - 1.1 | 1.1 - 1.11 |
| Low: | 1.03 - 1.04 | 1.04 - 1.04 |
| Close: | 1.04 - 1.05 | 1.05 - 1.06 |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Thu, 29 Jan 2026
AN2 Therapeutics adjusts leadership roles and executive compensation - TipRanks
Fri, 09 Jan 2026
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Wed, 07 Jan 2026
An2 therapeutics (ANTX): cfo Day sells $8883 in shares - Investing.com
Wed, 07 Jan 2026
Eizen, AN2 Therapeutics COO, sells $25k in ANTX stock - Investing.com
Wed, 12 Nov 2025
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 25.3 (%) |
| Held by Institutions | 39.3 (%) |
| Shares Short | 50 (K) |
| Shares Short P.Month | 41 (K) |
| EPS | -1.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.4 % |
| Return on Equity (ttm) | -46 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.93 |
| PEG Ratio | 0 |
| Price to Book value | 0.47 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|